Biology Reference
In-Depth Information
phocyte activity in Sydney Blood Bank Cohort patients infected with Nef-defective HIV type 1.
J Virol 73: 436±443.
Egan MA, Kuroda MJ, Voss G, Schmitz JE, Charini WA, Lord CI, Forman MA, Letvin NL.
1999. Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate
CD8() cytotoxic T lymphocytes speci®c for dominant and nondominant viral epitopes in sim-
ian-human immunode®ciency virus-infected rhesus monkeys. J Virol 73: 5466±5472.
Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. 1998. Highly active
antiretroviral therapy results in a decrease in CD8
T cell activation and preferential recon-
stitution of the peripheral CD4
T cell population with memory rather than naive cells [In
Process Citation]. Antiviral Res 39: 163±173.
Fiorentino S, Dalod M, Olive D, Guillet J-G, Gombard E. 1996. Predominant involvement of
CD8
CD28
ÿ
lymphocytes in human immunode®ciency virus-speci®c cytotoxic activity. J Virol
70: 2022±2026.
Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, Smith N, Sissons P, Rowland-
Jones S, Bell JI, Moss PA. 2000. Functional heterogeneity and high frequencies of cytomegalo-
virus- speci®c CD8() T lymphocytes in healthy seropositive donors [In Process Citation]. J
Virol 74: 8140±8150.
Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G,
Morgan B, Edwards A, et al. 1997a. Late escape from an immunodominant cytotoxic T-
lymphocyte response associated with progression to AIDS. Nat Med 3: 212±217.
Goulder PJ, Sewell AK, Lalloo DG, Price DA, Whelan JA, Evans J, Taylor GP, Luzzi G, Gian-
grande P, Phillips RE, McMichael AJ. 1997b. Patterns of immunodominance in HIV-1-speci®c
cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-
identical siblings with HLA-A*0201 are in¯uenced by epitope mutation. J Exp Med 185: 1423±
1433.
Gray C, Puren A. 2000. An immunology-based approach to the design of an HIV-1 preventative
vaccine. S Afr J Science 96: 347±350.
Gray CM, Schapiro JM, Winters MA, Merigan TC. 1998. Changes in CD4
and CD8
T cell
subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with
prior protease inhibitor experience. AIDS Res Hum Retroviruses 14: 561±569.
Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK,
Davis MM, Merigan TC. 1999. Frequency of class I HLA-restricted anti-HIV CD8
T cells in
individuals receiving highly active antiretroviral therapy (HAART). J Immunol 162: 1780±1788.
Gray C, Lawrence J, Ranheim E, Vierra M, Zupancic M, Winters M, Altman J, Montoya J,
Zolopa A, Schapiro J, et al. 2000. Highly active antiretroviral therapy results in HIV type 1
suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T
cells, and diminished frequencies of peripheral activated HIV type 1-speci®c CD8
T cells.
AIDS Res Human Retroviruses 16: 1357±1369.
Haase AT. 1999. Population biology of HIV-1 infection: viral and CD4
T cell demographics and
dynamics in lymphatic tissues. Annu Rev Immunol 17: 625±656.
Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A. 1999.
E¨ective induction of HIV-speci®c CTL by multi-epitope using gene gun in a combined vacci-
nation regime. Vaccine 17: 589±596.
Jin X, Demoitie MA, Donahoe SM, Ogg GS, Bonhoe¨er S, Kakimoto WM, Gillespie G, Moss,
PA, Dyer W, Kurilla MG, Riddell SR, Downie J, Sullivan JS, McMichael AJ, Workman C,
Nixon DF. 2000. High frequency of cytomegalouirus-speci®c cytotoxic T-e¨ector cells in HLA-
A*0201-positive subjects during multiple viral coinfections. J Infect Dis 181: 165±175.
Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. 1999. Levels of
human immunode®ciency virus type 1-speci®c cytotoxic T-lymphocyte e¨ector and memory re-
sponses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 73:
6721±6728.
